Home > Press > Emergency Filtration Products Issues FDA Update
Abstract:
Emergency Filtration Products, Inc. (EFP) (PINKSHEETS: EMFP) today announced that it has withdrawn the Company's 510(k) notification (510(k)) for its NanoMask product from current FDA review. EFP originally filed its initial 510(k) in 2006. The FDA review had been suspended pending EFP response to various FDA requests for additional information, some of which required the company to commission additional scientific testing. The deadline for responding to the FDA requests is October 5, 2007. However, EFP learned recently that the required testing will not be completed by that time.
EFP management believes that the company has made substantial progress in 2007 toward completing all of the additional scientific testing necessary to respond to the FDA information request. EFP in conjunction with Applied Nanoscience Inc. (ANI) (PINKSHEETS: APNN), the company with which EFP has announced a merger, has initiated all required testing and analyses. EFP has also retained well-known scientific and medical experts to ensure thorough scientific response to the FDA's information request. ANI has been assisting the funding of the ongoing testing and expects to continue to assist funding EFP to enable EFP to finalize the required testing in order to resubmit a 510(k) notification.
EFP intends to submit a new 510(k) notification as soon as the company is satisfied that all of the information requested by FDA staff is available and is scientifically sound. The schedule for completion of all required testing and preparation of a new FDA notification is imprecise due to the nature of the testing required. However, management currently estimates that a complete new 510(k) notification will be ready for submission to FDA around the middle of December.
"EFP's initial 510(k) submission to the FDA, which was made by the Company's former management, gave rise to significant comments by the FDA," said Philip Dascher, CEO, EFP. "As a result, EFP, in tandem with ANI, had to develop new testing protocols and perform testing at independent laboratories in order to satisfactorily answer the FDA's comments. Since we are braving new ground, working with emerging technologies, we have had to originate new ways of testing our product -- which have been reviewed by the FDA -- in order to verify its safety and effectiveness. This process has taken considerably more time than originally anticipated, but we expect to complete our testing and file a new 510(k) with the FDA before the end of the year if possible. Obviously, we want to complete the current testing and file our new FDA notification as soon as we possibly can. However, we will not rush this filing or the underlying scientific testing and analyses. We will file again with FDA just as soon as we are confident that we can provide all of the information they requested with a first-rate scientific basis."
####
About Emergency Filtration Products, Inc.
EFP was formed to develop a preeminent filtration technology that would serve to ensure the safety of rescuers by virtually eliminating risk of cross-contamination during CPR. Our goal was to elevate the confidence of caregivers to the point where fear of exposure to contagious disease would not cause even a moment's hesitation.
For more information, please click here
Contacts:
Philippe Niemetz
800-477-7570
or
212-344-6464
Emergency Filtration Products
Business Address
1111 Grier Drive
Suite B Las Vegas NV 89119
702.307.4102
Mailing Address
1111 Grier Drive
Suite B
Las Vegas NV 89119
Copyright © Market Wire
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Govt.-Legislation/Regulation/Funding/Policy
New discovery aims to improve the design of microelectronic devices September 13th, 2024
Physicists unlock the secret of elusive quantum negative entanglement entropy using simple classical hardware August 16th, 2024
Single atoms show their true color July 5th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||